Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers

Pancreatic cancer is on the rise, and is set to become the 2nd leading cause of cancer deaths by 2030. Its prognosis is very poor, with a 5-year survival rate of just 5.5%. Curative surgery with chemotherapy improves survival, but only 20% of patients are eligible. For locally advanced forms, radiotherapy, notably in the form of MRI-guided adaptive stereotactic radiotherapy (SMART), is showing promising results in terms of survival and local control, but still requires prospective validation.

NCT Number	NCT07097064
Lead Sponsor	Institut du Cancer de Montpellier - Val d'Aurelle
Conditions	Locally Advanced Pancreatic Adenocarcinoma
Enrollment	160 participants
Start Date	2025-09
Primary Completion	2028-09 (estimated)
Study Completion	2033-09 (estimated)
Updated on ClinicalTrials.gov	2025-07-31